Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Small (Weinheim an Der Bergstrasse, Germany)
|
September 25, 2008
Multiplexed lipid dip-pen nanolithography on subcellular scales for the templating of functional proteins and cell culture
Sylwia Sekula, Jeanette Fuchs, Susanne Weg-Remers, et al.
Cancer Immunology Research
|
September 10, 2025
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Hampus Andersson, Ida Uddbäck, Tova Hermodsson, et al.
Journal for Immunotherapy of Cancer
|
April 13, 2019
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, et al.
Oncoimmunology
|
April 2, 2020
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, et al.
Journal for Immunotherapy of Cancer
|
November 2, 2022
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Karin Hägerbrand, Laura Varas, Adnan Deronic, et al.
The Lancet. Oncology
|
June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
Cell Reports. Medicine
|
October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Nature Communications
|
December 16, 2021
CD137 (4-1BB) costimulation of CD8<sup>+</sup> T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, et al.
Molecular Cancer Therapeutics
|
November 7, 2022
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
Michelle H Nelson, Sara Fritzell, Robert Miller, et al.
Nature Communications
|
November 28, 2025
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer
Songul Kucukcelebi, Freek R van 't Land, Sjoerd H van der Burg, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Small (Weinheim an Der Bergstrasse, Germany)
|
September 25, 2008
Multiplexed lipid dip-pen nanolithography on subcellular scales for the templating of functional proteins and cell culture
Sylwia Sekula, Jeanette Fuchs, Susanne Weg-Remers, et al.
Cancer Immunology Research
|
September 10, 2025
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade
Hampus Andersson, Ida Uddbäck, Tova Hermodsson, et al.
Journal for Immunotherapy of Cancer
|
April 13, 2019
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, et al.
Oncoimmunology
|
April 2, 2020
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, et al.
Journal for Immunotherapy of Cancer
|
November 2, 2022
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Karin Hägerbrand, Laura Varas, Adnan Deronic, et al.
The Lancet. Oncology
|
June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
Cell Reports. Medicine
|
October 8, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, et al.
Nature Communications
|
December 16, 2021
CD137 (4-1BB) costimulation of CD8<sup>+</sup> T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, et al.
Molecular Cancer Therapeutics
|
November 7, 2022
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
Michelle H Nelson, Sara Fritzell, Robert Miller, et al.
Nature Communications
|
November 28, 2025
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer
Songul Kucukcelebi, Freek R van 't Land, Sjoerd H van der Burg, et al.
Page
of 4